278 related articles for article (PubMed ID: 9116302)
1. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
2. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
[TBL] [Abstract][Full Text] [Related]
3. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
Gambero S; Canalli AA; Traina F; Albuquerque DM; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Feb; 78(2):144-51. PubMed ID: 17313560
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
5. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
Cartron JP; Elion J
Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
[TBL] [Abstract][Full Text] [Related]
6. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
7. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
8. The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia.
Lee K; Gane P; Roudot-Thoraval F; Godeau B; Bachir D; Bernaudin F; Cartron JP; Galactéros F; Bierling P
Blood; 2001 Aug; 98(4):966-71. PubMed ID: 11493440
[TBL] [Abstract][Full Text] [Related]
9. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
[TBL] [Abstract][Full Text] [Related]
10. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
11. Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: a novel pathway involving alpha 4 beta 1 integrin receptors on sickle reticulocytes and fibronectin.
Kumar A; Eckmam JR; Swerlick RA; Wick TM
Blood; 1996 Dec; 88(11):4348-58. PubMed ID: 8943872
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
13. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells.
Brun M; Bourdoulous S; Couraud PO; Elion J; Krishnamoorthy R; Lapoumeroulie C
Pharmacogenomics J; 2003; 3(4):215-26. PubMed ID: 12931135
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
16. CD36-positive stress reticulocytosis in sickle cell anemia.
Browne PV; Hebbel RP
J Lab Clin Med; 1996 Apr; 127(4):340-7. PubMed ID: 8656036
[TBL] [Abstract][Full Text] [Related]
17. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
Chaar V; Laurance S; Lapoumeroulie C; Cochet S; De Grandis M; Colin Y; Elion J; Le Van Kim C; El Nemer W
J Biol Chem; 2014 Apr; 289(16):11512-11521. PubMed ID: 24616094
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist.
Lutty GA; Taomoto M; Cao J; McLeod DS; Vanderslice P; McIntyre BW; Fabry ME; Nagel RL
Invest Ophthalmol Vis Sci; 2001 May; 42(6):1349-55. PubMed ID: 11328750
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions.
Joneckis CC; Shock DD; Cunningham ML; Orringer EP; Parise LV
Blood; 1996 Jun; 87(11):4862-70. PubMed ID: 8639860
[TBL] [Abstract][Full Text] [Related]
20. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]